You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Novartis sets sights on potential COVID-19 antivirals from Molecular Partners

Swiss pharma company Novartis has inked an option and license agreement with Molecular Partners to develop, manufacture and commercialise the latter’s anti-COVID-19 DARPin programme.